$500 Million is the total value of CHI Advisors LLC's 21 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 34.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | New | CULLINAN ONCOLOGY INC | $91,774,000 | – | 2,202,407 | +100.0% | 18.37% | – |
| PLRX | Sell | PLIANT THERAPEUTICS INC | $91,434,000 | +70.9% | 2,324,795 | -1.3% | 18.30% | +21.5% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $78,588,000 | -9.5% | 2,560,703 | +1.1% | 15.73% | -35.7% |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $52,480,000 | – | 2,874,032 | +100.0% | 10.51% | – |
| ORTX | Buy | ORCHARD THERAPEUTICS PLCads | $29,417,000 | +132.3% | 4,051,972 | +38.2% | 5.89% | +65.1% |
| ONCR | Buy | ONCORUS INC | $24,663,000 | -54.6% | 1,771,786 | +5.5% | 4.94% | -67.7% |
| KROS | Sell | KEROS THERAPEUTICS INC | $24,649,000 | -19.5% | 400,468 | -7.7% | 4.94% | -42.8% |
| IKNA | New | IKENA ONCOLOGY INC | $23,017,000 | – | 814,756 | +100.0% | 4.61% | – |
| LRMR | LARIMAR THERAPEUTICS INC | $22,136,000 | -31.8% | 1,515,148 | 0.0% | 4.43% | -51.5% | |
| INZY | Sell | INOZYME PHARMA INC | $18,360,000 | -10.6% | 927,264 | -6.8% | 3.68% | -36.5% |
| FRLN | Buy | FREELINE THERAPEUTICS HLDGSsponsored ads | $17,033,000 | -31.5% | 1,384,743 | +1.7% | 3.41% | -51.3% |
| AKUS | Sell | AKOUOS INC | $11,901,000 | -31.1% | 858,027 | -1.5% | 2.38% | -51.0% |
| DTIL | Sell | PRECISION BIOSCIENCES INC | $7,158,000 | +0.7% | 691,629 | -18.9% | 1.43% | -28.5% |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $2,092,000 | +19.7% | 679,132 | +38.4% | 0.42% | -14.8% |
| GTHX | Sell | G1 THERAPEUTICS INC | $1,203,000 | +7.9% | 50,000 | -19.4% | 0.24% | -23.2% |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $1,038,000 | +47.2% | 174,169 | +29.0% | 0.21% | +4.5% |
| OVID | Sell | OVID THERAPEUTICS INC | $995,000 | -47.9% | 247,510 | -70.1% | 0.20% | -63.0% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $611,000 | -38.1% | 15,000 | -34.2% | 0.12% | -56.1% |
| ADVM | Sell | ADVERUM BIOTECHNOLOGIES INC | $396,000 | -38.3% | 40,209 | -32.1% | 0.08% | -56.4% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $340,000 | -44.9% | 3,500 | -36.4% | 0.07% | -60.9% |
| RARE | Sell | ULTRAGENYX PHARMACEUTICAL IN | $228,000 | -45.1% | 2,000 | -33.3% | 0.05% | -60.7% |
| DTIL | Exit | PRECISION BIOSCIENCES INCcall | $0 | – | -10,000 | -100.0% | -0.00% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INcall | $0 | – | -20,000 | -100.0% | -0.00% | – |
| XBI | Exit | SPDR SER TRput | $0 | – | -10,000 | -100.0% | -0.02% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -8,000 | -100.0% | -0.10% | – |
| AMWL | Exit | AMERICAN WELL CORPcl a | $0 | – | -248,352 | -100.0% | -1.77% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.